Letter | Published:

Direct evidence of two types of β adrenoceptor binding site in lung tissue

Abstract

THERE is much evidence to suggest that β adrenoceptors are not homogeneous—pharmacological data on the actions of β adrenoceptor agonists and antagonists in intact tissues indicate the presence of two broad subclasses β1 β2 (refs 1, 2), although there is some controversy regarding this strict subdivision3,4. The receptors found in heart and adipose tissue have been classified as β1 whereas those in liver, skeletal muscle, trachea and uterus have been designated β2. This classification has been supported by biochemical studies examining β adrenoceptor-mediated cyclic AMP formation in various tissues5–7, although the characterisation of the β adrenoceptor in lung tissue using this approach has been the subject of some debate6,8. The direct binding of radiolabelled β–adrenoceptor antagonists to tissue membrane preparations has been studied by several workers in an attempt to overcome some of the problems that may arise when examining this receptor indirectly9. We have examined the direct binding of the specific β adrenoceptor ligand 3H-dihydroalprenolol (DHA) to rat lung membranes and here we present evidence for the presence of both β1 and β2 adrenoceptor subtypes in this tissue in a ratio of approximately 1 : 3.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Lands, A. M., Arnold, A., McAulitt, J. P., Luduena, F. P. & Brown, T. G. Nature 216, 597–598 (1967).

  2. 2

    Farmer, J. B. & Levy, G. P. J. Pharm. Pharmac. 22, 145–146 (1970).

  3. 3

    Bristow, M., Sherrod, T. R. & Green, R. D. J. Pharmac. exp. Ther. 171, 52–61 (1970).

  4. 4

    Levy, B. J. Pharmac. exp. Ther. 186, 134–142 (1973).

  5. 5

    Burgess, R. A. & Blackburn, K. J. Nature new Biol. 235, 249–250 (1972).

  6. 6

    Lefkowitz, R. J. Biochem. Pharmac. 24, 583–590 (1975).

  7. 7

    Petrack, B. & Czernik, A. J. Molec. Pharmac. 12, 203–207 (1976).

  8. 8

    Coleman, A. J. & Somerville, A. R. Br. J. Pharmac. 58, 83–93 (1977).

  9. 9

    Wolfe, B. B., Harden, K. T. & Molinoff, P. B. A. Rev. Pharmac. Toxicol. 17, 575–604 (1977).

  10. 10

    Barnett, D. B., Nahorski, S. R. & Rugg, E. L. Br. J. Pharmac. 61, 459 (1977).

  11. 11

    Ulrych, M., Franciosa, J. A. & Conway, J. F. Clin. Pharmac. Ther. 13, 232–240 (1972).

  12. 12

    Dunlop, D. & Shanks, R. G. Br. J. Pharmac. 32, 201–218 (1968).

  13. 13

    Barrett, A. M., Carter, J., Fitzgerald, J. D., Hull, R. & Le Court, D. Br. J. Pharmac. 48, 340–343 (1973).

  14. 14

    Brittain, J. R., Jack, D. & Ritchie, A. C. Adv. Drug Res. 5, 197–253 (1970).

  15. 15

    Harms, H., Zaagsma, J. & De Vente, J. Life Sci. 21, 123–128 (1977).

  16. 16

    Carlsson, E. & Ablad, B. in Beta-adrenoceptor Blocking Agents (eds Saena, P. R. & Forsyth, R. P.) 305–310 (North Holland, Amsterdam, 1976).

  17. 17

    Furchgott, R. F., Wakade, T. D., Sorace, R. A. & Stollak, J. S. Fedn Proc. 34, 794 (1976).

  18. 18

    Jenkinson, D. H. Br. med. Bull. 29, 142–147 (1973).

  19. 19

    Triggle, D. J. & Triggle, C. R. in Chemical Pharmacology of the Synapse 277–284 (Academic, New York, 1976).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.